MRNA — Moderna Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $231.35
- YTD price return
- +684.50%
- YTD total return
- +684.50%
- Market cap
- 93.6B
- Enterprise value
- 96.6B
- Shares outstanding
- 404.6M
- 52W low
- $22.28
- 52W high
- $280.80
- From 52W high
- -17.61%
- From 52W low
- +938.38%
- 52W range
- 81%$22.28–$281
- Beta
- 0.88
Volume
- Rel volume
- 0.42×
- 30D volume
- 16.7M
- 30D $ vol
- 3.7B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$8.6M
- Insider net 3M
- −$33.9M
- Insider net 1Y
- −$80.9M
Form 4 transactions by trade date, as filed; latest on file 2026-10-15.
Fundamentals
- Sales (ttm)
- 2.5B
- Sales/share
- $6.24
- EPS (ttm)
- -$6.91
- FCF (ttm)
- -2B
- FCF/share
- -$4.87
- Book value/share
- $16.90
- Net margin
- -110.46%
- ROE
- -40.79%
- ROA
- -20.71%
- Debt / equity
- 0.52×
- Current ratio
- 3.62
Growth (CAGR, ttm) · 10Y
- Sales
- +13.14%-34.82%-26.58%+38.13%
- Shares
- +3.57%+2.00%-0.04%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +9.24%-36.10%-26.55%n/a
- Book value/share
- -29.26%-21.76%-7.51%n/a
- Price
- +767.44%+48.85%+0.01%n/a
- Total return
- +767.44%+48.85%+0.01%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -33.5×
- Fwd P/E
- -60.8×
- P/S (ttm)
- 37.1×
- P/B (mrq)
- 13.7×
- EV/Sales (ttm)
- 38.3×
- FCF yield (ttm)
- -2.10%
- Buyback yield (realized, 1y)
- -3.57%
- Shareholder yield (realized, 1y)
- -3.57%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 71st
- P/B
- 87th
Bar = where today’s multiple sits in MRNA’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-12#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m5Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m5Y n/mYoY n/mTTM: operating cash flow −$1.8B, capex −$185M
Q3 2026: operating cash flow −$1.6B, capex −$47M
Shares (diluted)
5Y +2.1%5Y +2.1%YoY +10.3%Net income
5Y n/m5Y n/mYoY n/mAbout Moderna#
Data provided bySource: Twelve DataModerna Inc. is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA) technology. Its commercial portfolio includes respiratory and infectious disease vaccines, while its broader pipeline spans oncology, rare diseases, autoimmune conditions, and other therapeutic areas. Moderna uses its mRNA platform to design products that instruct cells to produce proteins or immune responses relevant to prevention and treatment. The company also works with manufacturing and commercialization capabilities to support product development and distribution across major healthcare markets. Headquartered in Cambridge, Massachusetts, Moderna plays a significant role in the biopharmaceutical industry by advancing a new class of medicines across vaccines and therapeutics.
Cambridge, MA·4,700 employees·Biotechnology·modernatx.com·As of Oct 28, 2026
Recent filings#
- Nov 6Earnings · Earnings release — EPS $0.38 vs −$1.10 est. (+134.6%); revenue $1.31B (+29% y/y) 5.3%
- Sep 308-K · Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
- Sep 18-K · Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
- Jul 31Earnings · Earnings release — EPS −$1.97 vs −$1.97 est. (+0.0%); revenue $145.0M (+2% y/y) 5.4%
ETFs holding MRNA#
31 of the 193 ETFs ChartRow carries live hold MRNA. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 2.0% |
| XBI | SPDR S&P Biotech ETF | 1.4% |
| VHT | Vanguard Health Care ETF | 0.6% |
| VBR | Vanguard Small-Cap Value ETF | 0.5% |
| XLV | Health Care Select Sector SPDR Fund | 0.4% |
| VB | Vanguard Small-Cap ETF | 0.3% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.3% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +20.69% | -0.70% |
| JNJ | Johnson & Johnson | +7.50% | +1.11% |
| ABBV | AbbVie Inc. | +4.74% | -0.18% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +7.03% | +0.54% |
| MRK | Merck & Co. Inc. | +1.03% | -0.16% |
| NVS | Novartis AG | +11.41% | -0.04% |
| TMO | Thermo Fisher Scientific Inc. | +5.62% | -2.55% |
| AMGN | Amgen Inc. | +11.85% | -0.22% |
